COVID-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab)

COVID-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab)

Show other versions (1)

Despite numerous publications on COVID-19, at present, conceptual thinking of the problem is only at a nascence stage. Treatment of patients with ANCA-associated systemic vasculitis (AAV) during the COVID-19 pandemic is one of the relevant issues. Management of COVID-19 in AAV patients undergoing an...

Full description

Bibliographic Details
Main Authors:	T. V. Beketova, L. M. Blank, A. M. Lila
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2018-06-01
Series:	Научно-практическая ревматология
Subjects:	covid-19 rituximab b cells anca vasculitis granulomatosis with polyangiitis
Online Access:	https://rsp.mediar-press.net/rsp/article/view/2889

Similar Items

Serum B cell activating factor (BAFF) as a biomarker for induction of remission with rituximab in ANCA-associated vasculitis
by: Kazuyuki Tsuboi, et al.
Published: (2022-10-01)

Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy
by: Dario Roccatello, et al.
Published: (2022-03-01)

Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab)
by: T. V. Beketova, et al.
Published: (2020-09-01)

The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic
by: T. V. Beketova, et al.
Published: (2021-03-01)

Granulomatosis with polyangiitis with severe lung involvement: efficacy of anti-B cell therapy with Rituximab
by: T. V. Beketova, et al.
Published: (2021-07-01)

Update of Management of ANCA-Associated Vasculitis
by: Hoi San Tang, et al.
Published: (2021-12-01)

Childhood-Onset ANCA- Associated Vasculitis: single center experience from Central California
by: Deepika Singh, et al.
Published: (2023-07-01)

Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation
by: T. V. Beketova, et al.
Published: (2021-12-01)

THE 2016 EUROPEAN (EULAR/ERA-EDTA) RECOMMENDATIONS FOR THE DIAGNOSIS AND MANAGEMENT OF ANCA-ASSOCIATED SYSTEMIC VASCULITIS
by: T. V. Beketova
Published: (2017-03-01)

Recommendations of the Brazilian Society of Rheumatology for the induction therapy of ANCA-associated vasculitis
by: Alexandre Wagner Silva de Souza, et al.

Multiple Cutaneous Manifestations in ANCA-Positive Eosinophilic Granulomatosis with Polyangiitis before and after Biologic Therapy: Clinical and Histopathologic Characterization of a Paradigmatic Case
by: Giorgia Carnicelli, et al.
Published: (2022-12-01)

ANCA-ASSOCIATED VASCULITIS: HETEROGENEITY OF CLINICAL MANIFESTATIONS, PROGNOSIS, CURRENT OPPORTUNITIES OF PHARMACOTHERAPY
by: O.B. Yaremenko, et al.
Published: (2017-11-01)

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
by: Elena Treppo, et al.
Published: (2021-08-01)

Diagnostic algorithm for antineutrophil cytoplasmic antibody-associated systemic vasculitis
by: T V Beketova
Published: (2018-05-01)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
by: Frank B. Cortazar, et al.
Published: (2018-03-01)

COVID-19 in a patient with granulomatosis with polyangiitis: Management tactics
by: E. F. Iskhakova, et al.
Published: (2023-03-01)

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation
by: Yusuke Miyazaki, et al.
Published: (2020-06-01)

Hypophysitis Secondary to Small Vessel ANCA Vasculitis Treated With Rituximab
by: Nankee K. Kumar, AB, et al.
Published: (2024-03-01)

Rituximab, Cyclophosphamide, and Corticosteroids for ANCA Vasculitis: The Good, the Bad, and the Ugly
by: Roberta Fenoglio, et al.
Published: (2020-10-01)

Granulomatosis with polyangiitis: An atypical initial presentation
by: Catarina Vilaça Pereira, et al.
Published: (2022-01-01)

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
by: Mark E. McClure, et al.
Published: (2023-03-01)

Activation of natural killer cells by rituximab in granulomatosis with polyangiitis
by: Doris Urlaub, et al.
Published: (2019-12-01)

Primary Vasculitis in Childhood: GPA and MPA in Childhood
by: Mehul P. Jariwala, et al.
Published: (2018-08-01)

Antineutrophil cytoplasmic antibody-associated vasculitis, update on molecular pathogenesis, diagnosis, and treatment
by: Arman F, et al.
Published: (2018-11-01)

A Candidate Gene Approach to ANCA-Associated Vasculitis Reveals Links to the C3 and CTLA-4 Genes but not to the IL1-Ra And Fcγ-RIIa Genes
by: Ulf Persson, et al.
Published: (2013-12-01)

ANCA-associated vasculitis with cardiac valve vegetations in two teenage males: two case reports and a literature review
by: Alexandra Theisen, et al.
Published: (2022-10-01)

Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis
by: Thomas Hellmark, et al.
Published: (2019-03-01)

CLINICAL AND RADIOLOGICAL CHARACTERISTICS OF ANCA-ASSOCIATED VASCULITIS: 7 YEARS OF EXPERIENCE IN DIAGNOSIS AND TREATMENT
by: L. M. Kudelya, et al.
Published: (2020-03-01)

Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure
by: Robson JC, et al.
Published: (2018-01-01)

Clinical characteristics and long-term survival differences of the ANCA-associated vasculitis group: a cross-sectional study of 27 patients
by: Jolanta Dadonienė, et al.
Published: (2017-07-01)

CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients
by: Anouk von Borstel, et al.
Published: (2019-09-01)

Successful total hip arthroplasty in patients with anca-associated systemic vasculitis
by: T. V. Beketova, et al.
Published: (2019-11-01)

EXPERIENCE WITH EFFECTIVE COMBINED ANTI-B-CELL THERAPY WITH RITUXIMAB AND BELIMUMAB FOR REFRACTORY GRANULOMATOSIS WITH POLYANGIITIS (WEGENER'S) WITH SEVERE LUNG DAMAGE
by: T. V. Beketova, et al.
Published: (2017-03-01)

Granulomatosis with polyangiitis: a 17 year experience from a tertiary care hospital in Pakistan
by: Omar Irfan, et al.
Published: (2018-05-01)

Predictors of relapse in granulomatosis with polyangiitis: a multi-center study
by: Sara Safari, et al.
Published: (2022-10-01)

Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study
by: Arielle Mendel, et al.
Published: (2023-07-01)

Staphylococcus Aureus carriage and long-term Rituximab treatment for Granulomatosis with polyangiitis
by: Emilio Besada, et al.
Published: (2015-06-01)

Granulomatosis polyangiitis associated with meningeal involvement: response to rituximab therapy after failure of cyclophosphamide
by: M. Benucci, et al.
Published: (2013-05-01)

CLINICAL AND LABORATORY FEATURES OF ANCA ASSOCIATED VASCULITIS: EXPERIENCE AT A TERTIARY CARE HOSPITAL IN LAHORE, PAKISTAN
by: Muhammad Zeeshan Aslam, et al.
Published: (2021-02-01)

CLINICAL AND LABORATORY FEATURES OF ANCA ASSOCIATED VASCULITIS: EXPERIENCE AT A TERTIARY CARE HOSPITAL IN LAHORE, PAKISTAN
by: Muhammad Zeeshan Aslam, et al.
Published: (2021-02-01)